Skip to main content

Table 3 Treatment duration and reason for final cessation of everolimus treatment in the RCC group

From: Increased risk of everolimus-associated acute kidney injury in cancer patients with impaired kidney function

 

AKI group

Non-AKI group

P-value

Treatment duration (weeks)

18 (9, 35)

20 (12, 36)

NS

Total dose (mg)

1050 (615, 1913)

1173 (683, 1915)

NS

Discontinuation of drug

15 (71%)

53 (74%)

NS

Reason for discontinuation

  

NS

 Disease progression

10 (67%)

35 (66%)

 

 Adverse effect

2 (13%)

9 (17%)

 

 Self-withdrawal

3 (20%)

9 (17%)

 
  1. RCC, renal cell carcinoma; AKI, acute kidney injury; NS, not significant.